June 30, 2004 - New drug to prevent lasting brain damage
Pharmos is focused on helping people think more clearly -- with cannabis. The biotechnology company is developing cannabis-related compounds that don't have psychotropic effects as potential treatments for central nervous system disorders. Pharmos' lead drug candidate, dexanabinol, is a neuroprotective compound that could prevent lasting damage from traumatic brain injury. It has received FDA fast track status for this indication. The drug candidate may also limit post-surgery memory loss and cognitive impairment. Other targets for these compounds include stroke, neuropathic pain, multiple sclerosis, and Alzheimer's disease.
The information and materials on this Web site are provided for general informational purposes only and are not intended to be legal advice. We attempt to provide quality information, but the law changes frequently and varies from jurisdiction to jurisdiction. The information and materials provided are general in nature, and may not apply to a specific factual or legal circumstance. An attorney and client relationship should not be implied. Nothing on this Web site is intended to substitute for the advice of an attorney, therefore if you require legal advice please consult with a competent attorney licensed to practice in your jurisdiction. All attorneys, unless otherwise noted in website, are not certified by Texas Board of Legal Specialization. See Terms of Use.